From the Editor
Let’s increase our use of IUDs and improve contraceptive effectiveness in this country
The unintended pregnancy rate is too high in the United States, and the use of long-acting reversible contraceptives is too low. Expanding the...
David R. Kattan, MD, MPH, and Ronald T. Burkman, MD
Dr. Kattan is Family Planning Section Head, Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts.
Dr. Burkman is Professor, Department of Obstetrics and Gynecology, Tufts University School of Medicine, Boston, Massachusetts. He is an OBG Management Contributing Editor.
The authors report no financial relationships relevant to this article.

Although use of long-acting reversible contraception is increasing slowly in the United States, there is plenty of room for improvement, particularly among young women. Here, 2 experts address the nuances of choosing a method for a teenage patient.
In this Article
CASE: Teen patient asks to switch contraceptive methods
A 17-year-old nulliparous woman comes to your clinic for an annual examination. She has no significant health problems, and her examination is normal. She notes that she was started on oral contraceptives (OCs) the year before because of heavy menstrual flow and a desire for birth control but has trouble remembering to take them—though she does usually use condoms. She asks your advice about switching to a different method but indicates that she has lost her health insurance coverage.
What can you offer her as an effective, low-cost contraceptive?
Long-acting reversible contraception (LARC) methods are especially suited for adolescent and young adult women, for whom daily compliance with a shorter-acting contraceptive may be problematic. Five LARC methods are available in the United States, including a new levonorgestrel-releasing intrauterine system (LNG-IUS; Liletta), which received approval from the US Food and Drug Administration (FDA) this year. Like Mirena, Liletta contains 52 mg of levonorgestrel that is released over time. Liletta was introduced by the nonprofit organization Medicines360 and its commercial partner Actavis Pharma in response to evidence that poor women continue to lack access to LARC because of cost or problems with insurance coverage.1
For providers who practice in settings eligible for 340B pricing, Liletta costs $50, a fraction of the cost of alternative intrauterine devices (IUDs). The cost is slightly higher for non-340B providers but is still significantly lower than the cost of other IUDs. For health care practices, the reduced price of Liletta may make it feasible for them to offer LARC to more patients. The reduced pricing also makes Liletta an attractive option for women who choose to pay for the device directly rather than use insurance, such as the patient described above.
Patient experience with Liletta also is key. Not surprisingly, Liletta’s clinical trial found patient satisfaction to be similar to that of Mirena users.2 The failure rate is less than 1%, again comparable to Mirena. The rate of pelvic infection with Liletta use was 0.5%, also comparable to previously published data.3
One difference between Liletta and Mirena is that Liletta carries FDA approval for 3 years of contraceptive efficacy, compared with 5 years for Mirena. In order to make Liletta available to US patients now, Medicines360 decided to apply for 3-year contraceptive labeling while 5- and 7-year efficacy data are being collected. Like Mirena, Liletta is expected to provide excellent contraception for at least 5 years.
Source: Liletta [package insert]. Actavis Pharma, Parsippany, NJ; 2015.
The unintended pregnancy rate is too high in the United States, and the use of long-acting reversible contraceptives is too low. Expanding the...
The US unintended pregnancy rate has reached an all-time high. Two experts explore the roots of the problem (cost most paramount) and offer...
We do not use long-acting reversible contraceptives in the United States at the rate they are used in Europe, and we have a high unplanned...
According to the CDC, use of long-acting reversible contraception has increased 5-fold since 2002. Who is using it most often and when?
No pregnancies occurred in implant users during 229.4 women-years of follow-up, and only one pregnancy in 197.7 women-years of follow-up occurred...
Especially if long-acting reversible contraception is placed within 8 weeks of birth